Skip to main content

Table 1 Patient and tumor characteristics according to treatment type BCS and BCSR stages 0-II breast cancer 2007–2012 in metropolitan Detroit area (SEER)

From: A Bayesian network and heuristic approach for systematic characterization of radiotherapy receipt after breast-conservation surgery

 

Breast-conservation surgery

 

Breast-conservation surgery

 
 

without radiotherapy (BCS)

 

with radiotherapy (BCSR)

 

Variable

No

Row%

 

No

Row%

Total

All Patients

2517

(21.4)

 

9219

(78.6)

11736

Race/Ethnicity (R)

 White

1860

(21.0)

 

7007

(79.0)

8867

 Black

603

(23.5)

 

1964

(76.5)

2567

 Other

37

(16.6)

 

186

(83.4)

223

 Unknown

17

(21.5)

 

62

(78.5)

79

Age at diagnosis (A)

 ≤25

2

(40.0)

 

3

(60.0)

5

 26−50

480

(20.7)

 

1843

(79.3)

2323

 51−75

1279

(17.3)

 

6096

(82.7)

7375

 >75

756

(37.2)

 

1276

(62.8)

2032

 Unknown

0

(0.0)

 

1

(100.0)

1

Marital status (M)

 Single

347

(22.9)

 

1168

(77.1)

1515

 Married

1145

(18.6)

 

5022

(81.4)

6167

 Separated

19

(24.4)

 

59

(75.6)

78

 Divorced

228

(18.8)

 

982

(81.2)

1210

 Widowed

507

(30.4)

 

1161

(69.6)

1668

 Unmarried

0

(0.0)

 

2

(100.0)

2

 Unknown

271

(24.7)

 

825

(75.3)

1096

Insurance status (IN)

 Uninsured

24

(21.6)

 

87

(78.4)

111

 Medicaid

156

(25.5)

 

456

(74.5)

612

 Insured

2277

(21.0)

 

8573

(79.0)

10850

 Unknown

60

(36.8)

 

103

(63.2)

163

Year (Y)

 2007

491

(25.5)

 

1433

(74.5)

1924

 2008

440

(23.5)

 

1433

(76.5)

1873

 2009

434

(22.5)

 

1494

(77.5)

1928

 2010

340

(18.5)

 

1500

(81.5)

1840

 2011

417

(20.6)

 

1607

(79.4)

2024

 2012

395

(18.4)

 

1752

(81.6)

2147

AJCC Stage (S)

 0

1123

(33.5)

 

2230

(66.5)

3353

 I

826

(15.2)

 

4613

(84.8)

5439

 IIA

413

(19.1)

 

1752

(80.9)

2165

 IIB

155

(19.9)

 

624

(80.1)

779

Grade

 I

519

(18.5)

 

2290

(81.5)

2809

 II

787

(17.0)

 

3848

(83.0)

4635

 III

534

(16.9)

 

2633

(83.1)

3167

 IV

10

(21.7)

 

36

(78.3)

46

 Undetermined

667

(61.8)

 

412

(38.2)

1079

Tumor size (TS)a

 ≤5

434

(24.7)

 

1326

(75.3)

1760

 6−11

481

(16.3)

 

2478

(83.7)

2959

 12−17

422

(16.3)

 

2161

(83.7)

2583

 18−23

272

(18.2)

 

1223

(81.8)

1495

 24−29

173

(20.4)

 

674

(79.6)

847

 30−35

119

(20.3)

 

466

(79.7)

585

 36−41

62

(24.1)

 

195

(75.9)

257

 42−47

27

(20.0)

 

108

(80.0)

135

 48−53

36

(32.1)

 

76

(67.9)

112

 54−59

16

(38.1)

 

26

(61.9)

42

 60−65

10

(35.7)

 

18

(64.3)

28

 66−71

5

(29.4)

 

12

(70.6)

17

 72−77

4

(36.4)

 

7

(63.6)

11

 78−83

3

(33.3)

 

6

(66.7)

9

 84−89

9

(81.8)

 

2

(18.2)

11

 90−95

0

(0.0)

 

4

(100.0)

4

 96−101

4

(57.1)

 

3

(42.9)

7

 >101

5

(55.6)

 

4

(44.4)

9

 Unknown

435

(50.3)

 

430

(49.7)

865

Histology (H)b

 8201

97

(24.0)

 

307

(76.0)

404

 8211

24

(26.7)

 

66

(73.3)

90

 8230

41

(15.5)

 

223

(84.5)

264

 8480

39

(20.7)

 

149

(79.3)

188

 8500

1212

(16.7)

 

6026

(83.3)

7238

 8501

38

(13.7)

 

240

(86.3)

278

 8503

25

(25.5)

 

73

(74.5)

98

 8507

22

(25.9)

 

63

(74.1)

85

 8520

639

(53.7)

 

551

(46.3)

1190

 8522

78

(16.2)

 

403

(83.8)

481

 8523

215

(19.1)

 

909

(80.9)

1124

 Other

87

(29.4)

 

209

(70.6)

296

Behavior (B)

 In situ

1120

(33.5)

 

2224

(66.5)

3344

 Invasive

1397

(16.6)

 

6995

(83.4)

8392

Willingness/radiotherapy (W)c

 Not declined

2423

(20.8)

 

9219

(79.2)

11642

 Declined

94

(100.0)

 

0

(0.0)

94

Primary Site (P)

 C500

21

(32.3)

 

44

(67.7)

65

 C501

147

(25.5)

 

429

(74.5)

576

 C502

269

(19.6)

 

1101

(80.4)

1370

 C503

151

(20.6)

 

581

(79.4)

732

 C504

849

(18.8)

 

3668

(81.2)

4517

 C505

162

(19.0)

 

689

(81.0)

851

 C506

16

(25.0)

 

48

(75.0)

64

 C508

539

(20.9)

 

2038

(79.1)

2577

 C509

363

(36.9)

 

621

(63.1)

984

Degree/invasiveness (I)d

 F0

541

(18.8)

 

2342

(81.2)

2883

 F10

1119

(33.5)

 

2223

(66.5)

3342

 F20

779

(15.5)

 

4255

(84.5)

5034

 F30

26

(15.8)

 

139

(84.2)

165

 F40

8

(13.6)

 

51

(86.4)

59

 F50

15

(19.5)

 

62

(80.5)

77

 F60

1

(100.0)

 

0

(0.0)

1

 F987

28

(16.0)

 

147

(84.0)

175

  1. aTumor size is measure in ml
  2. bICD-O-3 Nomenclature: 8201 Cribriform carcinoma in situ, 8211 Tubular adenocarcinoma, 8230 Duct carcinoma in situ, solid type, 8480 Mucinous adenocarcinoma, 8500 Intraductal carcinoma, noninfiltrating, 8501 Comedocarcinoma, non-infiltrating, 8503 Noninfiltrating intraductal papillary adenocarcinoma, 8507 Intraductal micropapillary carcinoma, 8520 Lobular carcinoma in situ, 8522 Intraductal and lobular in situ carcinoma, 8523 Infiltr. duct mixed with other types of carcinoma, in situ
  3. cWillingness radiotherapy, is based upon the field denominated “RX SUMM–RADIATION” on the SEER data, from here the option of Patient refused radiation therapy were considered as “Declined"
  4. dDegree of tumor invasiveness was categorized with the field CS Site-Specific Factor 6 from SEER. The field records the code that indicates how the pathological tumor size was coded in tumor size. codification includes the levels: F0 Where the entire tumor reported as invasive, F10 Entire tumor reported as in situ, F20 Invasive and in situ components present (size of invasive component stated and coded in tumor size), F30 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and in situ described as minimal), F40 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and in situ described as extensive), F50 Invasive and in situ components present (size of entire tumor coded in tumor size because size of invasive component not stated and proportions of in situ and invasive not known), F60 Invasive and in situ components present (unknown tumor size coded), F987 Unknown if invasive and in situ components present
Back to article page

BMC Medical Informatics and Decision Making

ISSN: 1472-6947

Contact us